Approach
Our approach
The digital therapies from Germany are approved and clinically validated. Yet they rarely reach other countries. Here is why, and how DUX changes that.
Why these therapies do not reach you on their own
Most manufacturers are small companies. Each would have to start from scratch in every country on its own: approval, security testing, translation, adaptation to local care, and running servers in the country.
For a single product, this rarely pays off. That is why good therapies stay in Germany.
The route: one licence, one platform, one partner
DUX licenses the therapy content from German manufacturers. Every manufacturer gives its express consent for each country.
We rebuild the therapies on our platform. Each one is placed on the market or registered as a medical device in its own right, as your country requires.
We adapt language, content and care pathways to your country. Data is stored in your country.
You have one contracting partner for all therapies. DUX takes care of operation, updates, security and support.
How a collaboration starts
Conversation
We listen. Which programmes and goals do you have, and who pays for care?
Market and regulatory review
We clarify approval, data protection, hosting and procurement in your country.
Pilot
One indication, one region, measurable goals that you set.
Scale-up
More indications and regions on the same platform.
Contact
Let's talk about your programmes
In the first conversation, we listen: what are your goals, and who pays for care? 30 minutes with Christoph Eberhardt, on Microsoft Teams.